[{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Silodosin","moa":"||Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Xintian Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Xintian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Xintian Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Xintian Pharmaceutical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Silodyx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : CDSCO has approved Silodosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil (PDE5 inhibitor), a fixed dose combination for the treatment of benign prostatic hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2023

                          Lead Product(s) : Silodosin,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Xintian Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Xintian Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 22, 2022

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Albert Einstein Healthcare Network

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Albert Einstein Healthcare Network

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 24, 2015

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 08, 2014

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 31, 2012

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 27, 2012

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 15, 2012

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 15, 2010

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Study Phase : Phase IV

                          Sponsor : Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 14, 2010

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Sponsor : Chonnam National University Hospital | Kangdong Sacred Heart Hospital | Yeungnam University Hospital | Pusan National University Hospital | Seoul National University Hospital | Samsung Medical Center | Seoul St. Mary's Hospital | Korea University Guro Hos

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          JW Pharmaceutical

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 26, 2010

                          Lead Product(s) : Silodosin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank